Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and potentially billions of dollars worldwide. Promising data announced in 2012 with follow ups scheduled at various healthcare conferences this year coincided with the company’s recent listing on the OTCQB, which commenced Q1-2013. OneMedRadio spoke with the Del Mar CEO about these milestones.
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
All told, the Los Angeles-based company could have six to eight trials running simultaneously in the coming months.
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.